A once-daily pill helped people with type 2 diabetes lose significant weight in a major trial.
The drug, orforglipron, activates GLP-1 receptors to reduce appetite and blood sugar.
Participants lost up to 8% of body weight after one year.
Oral semaglutide produced about 4–5% weight loss in comparison.
Researchers studied more than 1,500 adults across several countries.
Orforglipron also lowered average glucose levels more effectively.
More patients stopped the new drug because of gastrointestinal side effects.
Still, experts see tablets as easier to use and store than injections.
Long-term safety and cardiovascular effects remain uncertain.
Specialists expect powerful oral incretin therapies to reshape diabetes treatment soon.
